{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68","upperLimit":"100","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Progression is defined as an increase of ≥ 25% from the lowest response value in any one or more of the following:\n\nSerum M-component with an absolute increase ≥ 0.5 g/dL; and/or Urine M-component with an absolute increase ≥ 200 mg/24 hours; and/or Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels (absolute increase must be \\>100mg/l) Bone marrow plasma cell percentage (absolute % must be ≥10% Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas Development of hypercalcemia (corrected serum calcium \\>11.5mg/100ml) that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"Study Treatment:\n\n200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses.","id":"OG000","title":"Anti-PD-1 (MK-3475)"}],"paramType":"NUMBER","populationDescription":"32 patients were enrolled. 3 withdrew consent prior to treatment. Of the 29 treated, 26 were evaluable for response (subjects who received 2-9 doses of MK-3475 were evaluable). Of the 26, 23 completed end-of-treatment response evaluation and were included in primary endpoint analysis.","reportingStatus":"POSTED","timeFrame":"2 Years","title":"The Estimated Percentage of Patients Alive Without Relapse or Progression at 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of patients"}